Predict your next investment

Corporation
HEALTHCARE | Drug Development
catalystpharma.com

See what CB Insights has to offer

Stage

IPO | IPO

Date of IPO

11/18/2006

Market Cap

0.57B

Stock Price

6.03

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases. Catalyst is currently developing amifampridine phosphate (with the proposed tradename of Firdapse) for the treatment of Lambert - Eaton Myasthenic Syndrome (LEMS). LEMS is a rare, autoimmune, neuromuscular disorder in which the body attacks and interferes with the communication between nerve and muscle cells primarily causing progressively severe muscle weakness and fatigue. Catalyst has completed a pivotal phase III, multi-centered clinical trial that showed amifampridine phosphate to be safe and effective in the treatment of patients with LEMS and is currently conducting a second, similar trial. Additionally, Catalyst is currently conducting a separate clinical trial of amifampridine phosphate in patients with Congenital Myasthenic Syndromes (CMS). Catalyst is also preparing to launch an additional clinical trial amifampridine phosphate in patients with MuSK Positive Myasthenia Gravis (MuSK-MG).

Catalyst Pharmaceuticals Headquarter Location

355 Alhambra Circle Suite 1250

Miami, Florida, 33134,

United States

305-420-3200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Catalyst Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Catalyst Pharmaceuticals is included in 2 Expert Collections, including Rare Diseases.

R

Rare Diseases

229 items

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Catalyst Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Catalyst Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.